Objective—Glucagon-like peptide 1 (GLP-1 ... Previous studies have focused on the improvements in β-cell function, while the inhibition of α-cell secretion has received less attention.

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

GLP-1 is a hormone made naturally in the gut. It plays a big role in managing blood sugar and appetite while releasing ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

Endometrial cancer (EC) ranks as the second most prevalent gynecologic malignancy globally, with approximately 189,000 new ...

"Palatin concludes Phase II trial of combination therapy for obesity" was originally created and published by Clinical Trials ...

Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...

They both likely accomplish this by improving cardiovascular disease risk factors such as improving blood sugar control, improving blood pressure, promoting weight less, reducing inflammation, and ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body shapes and sizes.